

FLUXERGY COVID-19

SAMPLE-TO-ANSWER-RT-PCR TEST

TEST OVERVIEW

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy's CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests with patient samples by researchers at University of California San Diego (UCSD).

- Real-Time RT-PCR
- Direct sample format (no nucleic acid extraction needed)
- Sample: Nasopharyngeal swab in UTM/VTM transport media
- Assay Target: SARS-CoV-2 nucleocapsid gene (N-gene) and the polyprotein gene, (orf1ab)
- Simple Workflow: Vortex swab sample in transport media, pipette sample into reaction mixture, and pipette into test card

FDA STATUS

Validation data was submitted to the FDA as part of Fluxergy's request for Emergency Use Authorization (EUA) on March 28th 2020.

*Fluxergy's products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy's products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use.




OUTLOOK - FUTURE COMBINATION TESTS AND SYNDROMIC PANELS

COMBINATION PCR AND SEROLOGY TEST

Fluxergy is working on the rapid development of a combination PCR and Serology test. This test is designed to give two pieces of information about a patient - whether or not the virus is currently present, as well as the immune response.

- Samples: Nasopharyngeal swab in UTM/VTM transport media for RT-PCR. Fingerpick whole blood or plasma for LFA
- Direct sample format (no nucleic acid extraction)
- Sample: Nasopharyngeal swab in UTM/VTM transport media
- Assay Target: SARS-CoV-2 nucleocapsid gene (N-gene) and the polyprotein gene, orf1ab.



SYNDROMIC PCR PANEL

Our syndromic panel, currently in our development pipeline, is designed to be able to differentiate between the presence of SARS-CoV-2 and influenza (common flu), and other respiratory pathogens. We anticipate our syndromic panel to be incredibly valuable during Flu season.

INCREASED MANUFACTURING CAPABILITY

On May 13th 2020, Fluxergy announced a \$30 million dollar investment into the manufacturing of our diagnostic platform in response to the COVID-19 pandemic. We anticipate that our significant investment to step up our manufacturing capability will enable Fluxergy to deliver as many as one million tests per month and reflects our confidence in our technology as an important and innovative solution in expanding COVID-19 testing capabilities.

*Fluxergy's products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy's products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy's objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.